Evidence map›Paper›PMID 33616851›Full record

ArticleHead and neck pathology2021

Myeloid Neoplasm with PDGFRA Rearrangement Manifesting as a Retromolar Pad Mass.

Amy S Duffield, Jonathan Webster, B Douglas Smith, Julius S Necciai, Austin McCuiston, Alisha D Ware

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Head and neck pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Amy S DuffieldDivision of Hematologic Pathology, Department of Pathology, The Johns Hopkins University School of Medicine, 401 N Broadway, Pathology Weinberg Bldg Suite 2242, Baltimore, MD, 21231, USA.
Jonathan WebsterDivision of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
B Douglas SmithDivision of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Julius S NecciaiThe Dental Center, Mount Airy, MD, USA.
Austin McCuistonDivision of Hematologic Pathology, Department of Pathology, The Johns Hopkins University School of Medicine, 401 N Broadway, Pathology Weinberg Bldg Suite 2242, Baltimore, MD, 21231, USA.
Alisha D WareDivision of Hematologic Pathology, Department of Pathology, The Johns Hopkins University School of Medicine, 401 N Broadway, Pathology Weinberg Bldg Suite 2242, Baltimore, MD, 21231, USA. agordy2@jhmi.edu.ORCID http://orcid.org/0000-0001-8145-3375
Sidney Kimmel Comprehensive Cancer Center · USJohns Hopkins University · USMemorial Sloan Kettering Cancer Center · USMurray State University · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
NCI NIH HHS P30 CA006973
6 · The paper itself

Abstract

Myeloid neoplasms with PDGFRA rearrangement are rare, and most commonly present with features of chronic eosinophilic leukemia; however, they rarely manifest as acute myeloid or lymphoblastic leukemia. Patients typically present with symptoms of hypereosinophilia including cardiovascular and pulmonary symptoms. An increase in mast cells is also a common feature of this disease, and there may be elevated serum tryptase with significant clinical overlap with systemic mastocytosis. Here, we present an unusual case of a myeloid neoplasm with PDGFRA rearrangement manifesting as a retromolar pad mass in a patient with a prior diagnosis of systemic mastocytosis. This case highlights the possibility of soft tissue involvement by myeloid neoplasms with PDGFRA rearrangement in the oral cavity. The identification of this entity is of significant clinical importance because many patients can be effectively treated with tyrosine kinase inhibitors.

Indexed as

AgedBiomarkers, TumorBiopsyDiagnosis, DifferentialGene RearrangementHumansHypereosinophilic SyndromeLeukemiaMaleMouth NeoplasmsSoft Tissue NeoplasmsBiomarkers, TumorEosinophiliaGingivaMastocytosisOral pathologyPDGFRA-associated myeloproliferative neoplasmTyrosine kinase inhibitor

Identifiers

PMID33616851
PMCPMC8633353
OpenAlexW3133427001

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.